Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14997857 | 0.86 | MAPT (0.58) | MEN1KMT2ASMN1; SMN2POLBRAB9A | |
| SCHEMBL10033649 | 0.83 | ALDH1A1 (0.46) | MEN1KMT2ASMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL10033639 | 0.83 | NAPRT (0.58) | MEN1KMT2ASMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL10033643 | 0.83 | RXFP1 (0.48) | KMT2ASMN1; SMN2L3MBTL1RAB9AALDH1A1 | |
| SCHEMBL10033645 | 0.82 | ALDH1A1 (0.50) | MEN1KMT2ASMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL10033644 | 0.80 | ALDH1A1 (0.41) | MEN1KMT2ASMN1; SMN2POLBRAB9A | |
| SCHEMBL10033642 | 0.78 | TRPV1 (0.41) | SMN1; SMN2POLBRAB9AALDH1A1MAPT | |
| SCHEMBL10033646 | 0.78 | RORC (0.50) | MEN1KMT2APOLBALDH1A1LMNA | |
| SCHEMBL27680037 | 0.78 | MEN1 (0.61) | MEN1KMT2ASMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL14997856 | 0.77 | PTGS2 (0.48) | ALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742156-B2 | Anti-viral carbamimidothioic acid esters | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2014-06-03 | — | — | US | disclosed |
| US-8742156-B2 | Anti-viral carbamimidothioic acid esters | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2014-06-03 | — | — | US | disclosed |
| US-20130143961-A1 | ANTI-VIRAL CARBAMIMIDOTHIOIC ACID ESTERS | BRITISH COLUMBIA CANCER AGENCY (CA) | 2013-06-06 | — | — | US | disclosed |
| US-20130143961-A1 | ANTI-VIRAL CARBAMIMIDOTHIOIC ACID ESTERS | BRITISH COLUMBIA CANCER AGENCY (CA) | 2013-06-06 | — | — | US | disclosed |
| WO-2012021991-A1 | ANTI-VIRAL CARBAMIMIDOTHIOIC ACID ESTERS | VERSITECH LIMITED (CN) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143961-A1 | ANTI-VIRAL CARBAMIMIDOTHIOIC ACID ESTERS | NAT10, RNGTT, NSUN2 | MEN1 3935/4885KMT2A 382/4885SMN1; SMN2 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.